valrox

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
BioMarin's Novel Treatment Promises to Disrupt Competitors
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Biomarin
gene therapy
valrox
hemophilia A
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Biomarin
valrox
gene therapy
hemophilia A
Flag link:
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
Motley Fool
Biomarin
JPMHC 2020
drug pricing
valrox
hemophilia
Flag link:
BioMarin talks down worries on gene therapy data differences
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Biomarin
gene therapy
hemophilia A
valrox
Flag link:
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Flag link:
How BioMarin May Revolutionize the Hemophilia Treatment Market
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Biomarin
gene therapy
hemophilia A
valrox
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Biomarin
hemophilia A
valrox
Flag link: